tergio 14 mg film-coated tablets
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - film-coated tablet - teriflunomide 14 mg - immunosuppressants
piperacillin/tazobactam viatris 2g/0.25g, powder for solution for infusion
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - powder for solution for infusion - piperacillin 2 g tazobactam 0.25 g - antibacterials for systemic use
piperacillin/tazobactam viatris 4g/0.5g, powder for solution for infusion
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - powder for solution for infusion - tazobactam 0.5 g piperacillin 4 g - antibacterials for systemic use
cardura xl 4 mg prolonged-release tablets
viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - prolonged-release tablet - doxazosin 4 mg - antihypertensives
scleryda 120 mg gastro-resistant hard capsules
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - gastro-resistant hard capsule - dimethyl fumarate 120 mg - immunosuppressants
scleryda 240 mg gastro-resistant hard capsules
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - gastro-resistant hard capsule - dimethyl fumarate 240 mg - immunosuppressants
sirkava 18 microgram, inhalation powder, hard capsule
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - inhalation powder hard capsule - tiotropium bromide 18 µg - drugs for obstructive airway diseases
dutrapro 0.5 mg soft capsules
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - soft capsule - dutasteride 0.5 mg - urologicals
brufen paediatric 100mg/5ml oral suspension
viatris healthcare limited - ibuprofen - oral suspension - ibuprofen
tobi podhaler
viatris healthcare limited - tobramycin - cystic fibrosis; respiratory tract infections - antibacterials for systemic use, - tobi podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. see sections 4.4 and 5.1 regarding data in different age groups.consideration should be given to official guidance on the appropriate use of antibacterial agents.